ANN ARBOR — Pharma startup Esperion Therapeutics announced this week the appointment of Jay P. Shepard as a Class III Director, with a term expiring at the 2019 annual meeting of stockholders. “Jay’s experience supporting the launch and commercialization of biopharmaceutical products will be invaluable as we advance the bempedoic acid product franchise through the
ANN ARBOR — Esperion Therapeutics Inc. announced positive top-line results from the third of five pivotal Phase 3 studies expected to be reported this year to evaluate the efficacy in lowering so-called bad cholesterol. The tests were done on Esperion's, lead drug candidate, bempedoic acid, at a dose of 180 milligrams, vs. placebo in high-risk patients
ANN ARBOR — Esperion Therapeutics Inc. Monday announced the start of a Phase 3 study to assess the safety and efficacy of a combination pill containing its cholesterol-fighter, bempedoic acid, with ezetimibe, a drug that decreases cholesterol absorption in the small intestine. Ezetimibe is used when other cholesterol-lowering medications, such as statins, are not tolerated
